BridgeBio Pharma BBIO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating lease liabilities (current)?
- BridgeBio Pharma (BBIO) reported operating lease liabilities (current) of $4.44M in Q1 2026.
- How has BridgeBio Pharma's operating lease liabilities (current) changed year-over-year?
- BridgeBio Pharma's operating lease liabilities (current) decreased by 14.8% year-over-year, from $5.21M to $4.44M.
- What is the long-term trend for BridgeBio Pharma's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities (current) has grown at a 10.3% compound annual growth rate (CAGR), from $3.8M to $6.19M.
- What does operating lease liabilities (current) mean?
- The portion of rent and lease payments due within the next year.
- How do you interpret operating lease liabilities (current)?
- Stable or predictable levels indicate consistent operational footprint, while sudden changes may reflect office expansion or consolidation.
- How does operating lease liabilities (current) compare across companies?
- Lease liabilities are standard for companies with physical research facilities and are generally consistent across peer groups.